Roivant Sciences Ltd. (ROIV): Capital Expenditures
$8.21M
Year ended 2026-03-31
$4.59M
Trailing 12 months to 2026-06-30
-13.5%
3-year compound annual growth
+7.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $8.21M | +78.5% | 2026-05-20, From 2025-04-01 |
| 2025-03-31 | $4.60M | +232.8% | 2026-05-20, From 2024-04-01 |
| 2024-03-31 | $1.38M | -89.1% | 2026-05-20, From 2023-04-01 |
| 2023-03-31 | $12.69M | -27.2% | 2025-05-29, From 2022-04-01 |
| 2022-03-31 | $17.44M | +200.3% | 2023-06-28, From 2021-04-01 |
| 2021-03-31 | $5.81M | n/a | 2022-06-28, From 2020-04-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $8.21M | +78.5% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $111.0K | -8.3% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $72.0K | +75.6% |
| Adagene Inc. (ADAG) | 2025-12-31 | $17.1K | -49.2% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $719.0K | +96.4% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $799.0K | -74.0% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $43.0K | -74.1% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $0 | -100.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
Compare ROIV, ACRS, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗